SCHEMBL19902580

SCHEMBL19902580

O=C(N[C@H]1CC[C@H](c2n[nH]c(=O)c3ccccc32)CC1)c1cnc(O)c(Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPGDS O60760 5/20 0.42
ROCK2 O75116 2/20 0.42
ROCK1 Q13464 1/20 0.38
NPC1 O15118 3/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
PARP1 P09874 1/20 0.37
LIPG Q9Y5X9 1/20 0.37
RAB9A P51151 2/20 0.37
ALDH1A1 P00352 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
ADRA2A P08913 1/20 0.37
MCHR1 Q99705 1/20 0.37
IP6K1 Q92551 1/20 0.37
MAPK8 P45983 1/20 0.36
SMYD3 Q9H7B4 2/20 0.36
BRD4 O60885 1/20 0.36
MAPK11 Q15759 1/20 0.36
MAPK14 Q16539 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17452856 0.88 ROCK2 (0.56) HPGDSROCK2ROCK1NPC1MEN1
SCHEMBL20229652 0.82 ROCK2 (0.41) HPGDSROCK2ROCK1NPC1LIPG
SCHEMBL19902490 0.79 HPGDS (0.48) HPGDSROCK2ROCK1NPC1RAB9A
SCHEMBL19902362 0.79 ROCK2 (0.42) HPGDSROCK2ROCK1ALDH1A1L3MBTL1
SCHEMBL19902710 0.79 GPR183 (0.44) HPGDSROCK2ALDH1A1
SCHEMBL19902356 0.77 CHRNA7 (0.45) ROCK2ROCK1NPC1PARP1RAB9A
SCHEMBL19902369 0.77 ROCK2 (0.46) ROCK2ROCK1NPC1MEN1KMT2A
SCHEMBL19902696 0.76 NPC1 (0.50) ROCK2ROCK1NPC1MEN1KMT2A
SCHEMBL19902383 0.76 CYP1A2 (0.48) ROCK2NPC1MEN1KMT2ARAB9A
SCHEMBL19902384 0.76 ROCK2 (0.41) HPGDSROCK2ROCK1NPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2018-06-07 US disclosed
US-9902702-B2 Spirocycloheptanes as inhibitors of rock BRISTOL-MYERS SQUIBB COMPANY (US) 2018-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK ROCK1, MYLK, ROCK2 HPGDS 609/4885ROCK2 3/4885ROCK1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.